LSTA Share Price Performance
US$4.63
2.05 (79.46%)
48.6% undervalued intrinsic discount
US$9.00
Fair Value
Price US$4.63
AnalystLowTarget US$9.00
AnalystConsensusTarget US$13.00
AnalystHighTarget US$15.00
Fair ValueUS$9.00
Share Pricen/a
Lisata Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
LSTA Community Narratives
AN
Fair Value US$9 48.6% undervalued intrinsic discount
Long Patent Tail And Partnering Delays Will Pressure Biotech Until Late Clinical Progress Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$13 64.4% undervalued intrinsic discount
Positive Clinical Trials Will Expand Precision Oncology Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$15 69.1% undervalued intrinsic discount
Breakthrough Trials And Global Trends Will Redefine Oncology
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Positive Clinical Trials Will Expand Precision Oncology Markets
Key Takeaways Strong clinical progress, strategic partnerships, and robust patent protection position Lisata for future growth and competitive advantage in oncology therapeutics. Prudent cost management and near-term non-dilutive funding enhance financial sustainability and support ongoing development and commercialization efforts.Read more
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$13
64.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
83.83% p.a.
Profit Margin
16.72%
Future PE
100.44x
Price in 2029
US$11.72
Long Patent Tail And Partnering Delays Will Pressure Biotech Until Late Clinical Progress Emerges
Catalysts About Lisata Therapeutics Lisata Therapeutics is a clinical stage biotech company focused on developing certepetide as a tumor targeting agent in combination with existing cancer therapies. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
48.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
88.79% p.a.
Profit Margin
16.24%
Future PE
66.96x
Price in 2029
US$8.22
Breakthrough Trials And Global Trends Will Redefine Oncology
Key Takeaways Breakthrough potential in solid tumor therapies and extended exclusivity position the company for long-term, high-margin growth with minimal generic competition. AI-driven innovation, strategic partnerships, and a strong pipeline in oncology are set to diversify revenue streams and enhance profitability.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
69.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
152.5% p.a.
Profit Margin
16.24%
Future PE
46x
Price in 2028
US$18.14
Trending Discussion
Recently Updated Narratives
AN
LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade
Fair Value: US$13 64.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Patent Tail And Partnering Delays Will Pressure Biotech Until Late Clinical Progress Emerges
Fair Value: US$9 48.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares
Fair Value: US$15 69.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lisata Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.07
- 100.00%
- -1,704.86%
- 0%
About LSTA
- Founded
- 1980
- Employees
- 26
- CEO
- WebsiteView website
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
